<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6051">
  <stage>Registered</stage>
  <submitdate>9/03/2016</submitdate>
  <approvaldate>9/03/2016</approvaldate>
  <nctid>NCT02723994</nctid>
  <trial_identification>
    <studytitle>A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia</studytitle>
    <scientifictitle>A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AALL1521</secondaryid>
    <secondaryid>INCB 18424-269</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>B-cell Acute Lymphoblastic Leukemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ruxolitinib
Treatment: drugs - Asparaginase Erwinia Chrysanthemi
Treatment: drugs - Cyclophosphamide
Treatment: drugs - Cytarabine
Treatment: drugs - Dexamethasone
Treatment: drugs - Doxorubicin
Treatment: drugs - Leucovorin Calcium
Treatment: drugs - Mercaptopurine
Treatment: drugs - Methotrexate
Treatment: drugs - Pegaspargase
Treatment: drugs - Prednisone
Treatment: drugs - Thioguanine
Treatment: drugs - Vincristine Sulfate

Experimental: Ruxolitinib in combination with chemotherapy - 


Treatment: drugs: Ruxolitinib
In Part 1, ruxolitinib will be administered at a protocol-defined starting dose in combination with chemotherapy, with dose escalation and de-escalation following the rolling 6 study design. The established recommended starting dose will be taken forward into Part 2.

Treatment: drugs: Asparaginase Erwinia Chrysanthemi


Treatment: drugs: Cyclophosphamide


Treatment: drugs: Cytarabine


Treatment: drugs: Dexamethasone


Treatment: drugs: Doxorubicin


Treatment: drugs: Leucovorin Calcium


Treatment: drugs: Mercaptopurine


Treatment: drugs: Methotrexate


Treatment: drugs: Pegaspargase


Treatment: drugs: Prednisone


Treatment: drugs: Thioguanine


Treatment: drugs: Vincristine Sulfate


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Part 1: Safety/tolerability of ruxolitinib in combination with chemotherapy as measured by adverse events (AEs), vital signs, clinical laboratory tests, and echocardiograms</outcome>
      <timepoint>Part 1: AEs assessed from screening through up to 30 days after the last dose of study drug, expected to be 26 months (females) or 38 months (males)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Part 2: Efficacy of ruxolitinib in combination with chemotherapy as measured by Event-free survival, defined as the percentage of patients alive without relapse, progression, or death at 3 years from study Day 1</outcome>
      <timepoint>Part 2: assessed at 3 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability of the combination treatment for subjects beginning treatment at the recommended dose for Part 2, as assessed by AEs, vital signs, clinical laboratory tests, and echocardiograms</outcome>
      <timepoint>AEs assessed from screening through up to 30 days after the last dose of study treatment, expected to be 26 months (females) or 38 months (males)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  De novo high-risk (HR) Ph-like B-ALL for which any of following criteria are present
             at diagnosis:

               -  Age = 10 years

               -  White blood cell (WBC) = 50 × 10^3/µL

               -  CNS3 leukemia

          -  One of the following Ph-like ALL genetic lesions must be present in the diagnostic
             bone marrow or peripheral blood sample:

               -  CRLF2 rearrangement with JAK1 or JAK2 mutation (JAK+)

               -  CRLF2 rearrangement without JAK mutation

               -  Other JAK pathway alterations (eg, JAK2 fusions, erythropoietin receptor (EPO-R)
                  fusions, SH2B3 deletions, interleukin-7 receptor-alpha (IL7RA) mutations) with or
                  without CRLF2 rearrangement

          -  Completed a 4-drug Induction therapy regimen (modified aBFM regimen or equivalent) in
             Study AALL1131 or as the institutional standard of care for HR B-ALL and have had
             end-Induction minimal residual disease (MRD) assessed

          -  Male and female subjects of reproductive non childbearing potential or willing to take
             appropriate precautions to avoid pregnancy or fathering a child for the duration of
             study participation</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Year</inclusiveminagetype>
    <inclusivemaxage>21</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Receipt of any other cytotoxic chemotherapy before Induction therapy, with exception
             of hydroxyurea or steroid pretreatment

          -  Trisomy 21 (Down syndrome)

          -  BCR-ABL1-rearranged (Ph+) ALL

          -  Calculated creatinine clearance or radioisotope glomerular filtration rate &lt; 70
             mL/min/1.73 m^2

          -  Alanine aminotransferase = 3 × upper limit of normal (ULN) for age

          -  Direct bilirubin = 1.5 × ULN (may be assumed if total bilirubin is below ULN)

          -  History or evidence of cirrhosis

          -  Platelet count &lt; 75 × 10^3/µL

          -  Absolute neutrophil count (ANC) &lt; 750/µL

          -  Positive screen for hepatitis B or C

          -  Known human immunodeficiency virus infection</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional(has expanded access)</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>170</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/05/2024</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital> - South Brisbane</hospital>
    <hospital> - Parkville</hospital>
    <postcode> - South Brisbane</postcode>
    <postcode> - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Incyte Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Children's Oncology Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent
      chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the
      study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy
      regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the
      recommended dose determined in Part 1.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02723994</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Albert Assad, MD</name>
      <address>Incyte Corporation</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Incyte Corporation Call Center</name>
      <address />
      <phone>1.855.463.3463</phone>
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>